Skip to main content

Waters' Q2 Profit Recedes, Dragging Down Shares

NEW YORK (GenomeWeb News) – Waters today reported that second-quarter revenue increased 6 percent as net income fell 12 percent on increased expenses, causing shares to slide 8.8 percent, or $3.75, to $38.85 in mid-afternoon trading.
Total receipts for the three months ended July 1 increased to $302 million from $285 million year over year. Waters said it is seeing strong demand for its Acquity UPLC technology.
Profit in the quarter declined to $48 million, or $.46 per share, from $54 million, or $.47 per share, last year. The company reported about $3 million in restructuring costs while expenses increased 7 percent in the quarter.
R&D spending increased 25 percent to about $20 million from $16 million in the year-ago period.
As of July 1, Waters had $490 million in cash and cash equivalents.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.